Peptides having antibacterial, anti-inflammatory or tissue regeneration capabilities and uses thereof
By developing peptides with specific amino acid sequences, the problem of insufficient antibacterial, anti-inflammatory and tissue regeneration capabilities in periodontal disease and periimplantitis was solved, and the antibacterial, anti-inflammatory and cell penetration of the peptides was achieved, which significantly improved the periodontal Regeneration effect of tissue.
Patent Information
- Application Number
- CN202380021930.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-15
- Filing Date
- 2023-02-14
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to have antibacterial, anti-inflammatory and tissue regeneration capabilities at the same time. Especially in the treatment of periodontal diseases and periimplant inflammation, traditional antibiotics are difficult to penetrate the biofilm, and the transplanted material cannot perform regeneration functions in an inflammatory environment.
Develop a peptide composed of specific amino acid sequences with antibacterial, anti-inflammatory and cellular permeability in pharmaceutical compositions and transplant materials to enhance therapeutic effects on periodontal disease and improve the conjugation with other peptides Cell permeability.
This peptide can effectively inhibit inflammation and bacterial growth, penetrate biofilm, significantly improve the regeneration effect of periodontal tissue, and does not require additional preparations to support its cell penetration, significantly improving the therapeutic effect of periodontitis and periimplantitis.
Smart Images

Figure CN118946576A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to a peptide having antibacterial, anti-inflammatory or tissue regeneration capabilities and uses thereof. Background Art
[0002] Many diseases and conditions are not only accompanied by bacterial infections caused by various bacteria, but also by inflammatory diseases. In particular, oral diseases, etc., are often accompanied by bacterial infections and inflammatory diseases. For example, in order to ensure that the treatment of periodontal diseases such as periimplantitis, periodontitis, and gingivitis is carried out normally, antibacterial and anti-inflammatory treatments must be carried out simultaneously. In addition to periodontal diseases, the damaged parts after tooth scaling or the state of the extraction socket after tooth extraction also require antibacterial and anti-inflammatory treatments. Therefore, it is necessary to develop substances that can be effectively applied to these diseases and conditions.
[0003] In addition, more than 700 species of microorganisms inhabit the oral cavity, and various bacteria attach to the tooth surface to form biofilms, which can cause gingivitis, periodontitis, and peri-implantitis. When a biofilm is formed, it is difficult for external substances to penetrate because the biofilm forms a physically thick layer, and because of gene mutations that occur through interactions between cells within the biofilm, it is known that resistance to antibiotics is about 1,000 times higher than that of planktonic bacteria. Therefore, when biofilm formation is inhibited or removed, gingivitis, periodontitis, or peri-implantitis caused by bacterial infection can be more effectively prevented or treated.
[0004] Traditionally, transplant materials used for tissue regeneration can only play a regenerative role in areas without inflammation. If inflammation occurs after transplantation, the regenerative function cannot be played. Therefore, when substances with antibacterial and anti-inflammatory effects are used together with transplant materials, inflammation that may occur in the early stage can be suppressed, thereby achieving regeneration of damaged tissues. For example, for periodontal tissues damaged by periodontitis, if substances with antibacterial and anti-inflammatory effects are used in combination with transplant materials, the alveolar tissue regeneration effect can be easily achieved. Summary of the invention
[0005] Technical issues
[0006] The present disclosure aims to provide a peptide with anti-inflammatory ability.
[0007] The present disclosure aims to provide a peptide having antibacterial ability at the cellular level and in biofilms.
[0008] The present disclosure aims to provide a peptide having cell-penetrating ability.
[0009] The present disclosure aims to provide a pharmaceutical composition comprising a peptide having anti-inflammatory or antibacterial ability.
[0010] The present disclosure aims to provide a transplant material comprising a peptide having anti-inflammatory or antibacterial ability.
[0011] Technical Solution
[0012] The peptide according to the embodiment is a peptide represented by the amino acid sequence of SEQ ID NO: 1.
[0013] The pharmaceutical composition according to the embodiment comprises the peptide represented by the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
[0014] The transplant material according to the embodiment contains the peptide represented by the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
[0015] Details of other aspects of the invention are included in the detailed description which follows.
[0016] Effects of the Invention
[0017] The peptides according to the embodiments have anti-inflammatory or antibacterial capabilities and thus can be used to treat inflammatory diseases or bacterial diseases or disorders.
[0018] The peptide according to the embodiment has cell permeability, so there is no need to attach additional peptides or add other agents for cell permeation of the peptide. In addition, by conjugating with other peptides with low cell permeability, cell permeation of other peptides can be assisted.
[0019] The transplant material according to the embodiment has anti-inflammatory or antibacterial ability, and thus can be effectively applied to periodontal disease sites such as periimplantitis and periodontitis, and can achieve tissue regeneration effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the result of analyzing the purity of the peptide using liquid chromatography after synthesis. The peptide has the amino acid sequence of SEQ ID NO: 1.
[0021] Figure 2 This is the result of analyzing the molecular weight of a peptide synthesized by mass spectrometry. The peptide has the amino acid sequence of SEQ ID NO: 1.
[0022] Figure 3 The results of enzyme immunoassay (ELISA) for IL-6 and TNF-α are shown.
[0023] Figure 4 The results of Western blot analysis of pNFkB and plkBa are shown.
[0024] Figure 5 The results of measuring the antibacterial ability of a peptide having the amino acid sequence of SEQ ID NO: 1 are shown.
[0025] Figure 6 The results of treating biofilms with a peptide having the amino acid sequence of SEQ ID NO: 1 are shown.
[0026] Figure 7 The graph shows the results of analyzing the intracellular penetration of a peptide having the amino acid sequence of SEQ ID NO: 1 using a confocal microscope.
[0027] Figure 8 The degree of intracellular penetration of a peptide having the amino acid sequence of SEQ ID NO: 1 into rabbit gingival tissue is shown.
[0028] Fig. 9 The extent of intracellular penetration of a peptide having the amino acid sequence of SEQ ID NO: 1 into adult canine gingival tissue is shown.
[0029] Fig.10 The results of measuring the antibacterial ability of a collagen sponge containing a peptide having the amino acid sequence of SEQ ID NO: 1 are shown.
[0030] Fig.11 and Fig.12 Numerical values indicate the results of periodontal tissue regeneration and the degree of alveolar bone regeneration confirmed by radiography in an adult canine periodontitis model treated with a collagen gel containing a peptide having the amino acid sequence of SEQ ID NO: 1. The squares indicate the alveolar bone regenerated by the transplant material. DETAILED DESCRIPTION
[0031] Hereinafter, the embodiments will be described in detail so that those skilled in the art can easily implement the present invention. The embodiments can be implemented in various ways and are not limited to the specific embodiments described herein.
[0032] Unless some terms used in the present disclosure are defined differently below, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0033] The techniques and processes described in the present disclosure are generally performed according to conventional methods, which are presented throughout the text. Generally, the nomenclature used in the present disclosure and the laboratory procedures in molecular biology, biochemistry, analytical chemistry, and cell culture are well known in the art and are the same as commonly used.
[0034] In one aspect, the present disclosure relates to a peptide having anti-inflammatory or antibacterial ability. The peptide is a peptide having an amino acid sequence of the following sequence 1.
[0035] Sequence 1: GKCSTRGRKSSRRKK
[0036] In one embodiment, after treatment with a peptide having the amino acid sequence of sequence 1, the intracellular release of inflammatory markers IL-6 and TNF-α was measured by enzyme immunoassay (ELISA), and it was confirmed that the peptide having the amino acid sequence of sequence 1 exhibited an anti-inflammatory ability that was almost similar to that of the cytokine IL-4 having an anti-inflammatory effect. In addition, the inhibitory effect of the peptide having the amino acid sequence of sequence 1 on the expression of the inflammation-related enzyme pNF-κB was confirmed by Western blotting, and the results confirmed that the peptide having the amino acid sequence of sequence 1 inhibited the expression of pNF-κB induced by LPS.
[0037] In another embodiment, it has been confirmed that the peptide having the amino acid sequence of SEQ ID NO. 1 has excellent antibacterial activity against periodontitis-causing bacteria such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis, and has been confirmed to exhibit the same or similar antibacterial activity as minocycline, which is commonly used in the treatment of periodontitis. In addition, the result of treating an artificial biofilm made with periodontitis-causing bacteria with the peptide having the amino acid sequence of SEQ ID NO. 1 confirmed that it has antibacterial activity and further has cell penetration ability.
[0038] In another aspect, the present disclosure relates to a peptide having cell-penetrating ability.
[0039] In one embodiment, it is confirmed by in vitro and in vivo experiments that a peptide having an amino acid sequence of sequence 1 penetrates into cells. Specifically, mouse macrophages (RAW264.7) were treated with a peptide having an amino acid sequence of sequence 1 to confirm whether they penetrate into the cells, and the result confirmed that the peptide having an amino acid sequence of sequence 1 penetrated into the cells. In addition, it has been confirmed that the peptide having an amino acid sequence of sequence 1 penetrates not only at the cellular level but also at the tissue level. When the gingival tissue of living rabbits and the gingival tissue of adult dogs were treated with a peptide having an amino acid sequence of sequence 1, it was confirmed that the peptide penetrated into the gingival tissue of rabbits and the gingival tissue of adult dogs.
[0040] In periodontitis or peri-implantitis, various periodontitis-inducing bacteria gather into communities to form thick biofilms. For this biofilm, it is difficult to remove it by only applying antibiotics because of the increased resistance to antibiotics. Therefore, it is necessary to penetrate this biofilm and at the same time have antibacterial ability to the periodontitis-inducing bacteria that constitute the biofilm. For the peptide with the amino acid sequence of sequence 1, it can penetrate into the cell itself, so there is no need to use an additional carrier. Therefore, it can penetrate the biofilm formed on the teeth and show antibacterial ability or easily penetrate into the gingival tissue. Further, by utilizing such cell / tissue penetration ability, the cell penetration ability is given by chemical conjugation with a peptide that has no cell penetration ability but has anti-inflammatory function, so that the desired anti-inflammatory effect can be increased.
[0041] In yet another aspect, the present disclosure relates to a pharmaceutical composition comprising a peptide having the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
[0042] The pharmaceutical composition can be effectively used to treat dental infectious diseases, and the dental infectious diseases can be selected from the group consisting of periodontitis, gingivitis and peri-implantitis.
[0043] The peptide may contain 10 parts by weight of the total 100 parts by weight of the composition for treating dental infection diseases. -3 ~10 parts by weight, more preferably 10 -2 ~10 -1 This is because if the peptide content is less than 10 -3 If the peptide content is more than 10 parts by weight, the antibacterial or anti-inflammatory effect is not significant, and if the peptide content is greater than 10 parts by weight, the effect will not increase proportionally, so there is no practical benefit in increasing the content.
[0044] The composition for treating dental infection diseases may further contain one or more selected from the group consisting of propolis, xylitol and protease. By further containing propolis or xylitol, the functional properties can be improved, and by adding protease, the antibacterial effect and lipopolysaccharide removal effect can be improved.
[0045] The pharmaceutically acceptable carrier of the composition for treating dental infection diseases can be selected from the group consisting of excipients such as starch, lactose, calcium carbonate, calcium phosphate, etc., binders such as starch, gum arabic, carboxymethyl cellulose, hydroxymethyl cellulose, crystalline cellulose, etc., lubricants such as magnesium stearate, talc, etc., disintegrators such as carboxymethyl cellulose calcium, talc synthetic aluminum silicate, etc., diluents such as water, vegetable oil, etc. and mixtures thereof.
[0046] The dosage form of the composition for treating dental infectious diseases is not particularly limited, but it can be formulated into powder, microgranules, liquid, powder, spray, ointment and gel preparations, and is most preferably formulated into a gel preparation.
[0047] In addition, regarding the dosage form when the peptide of the present invention is mixed into the composition for treating inflammation, it can be mixed by conventional ingredients and methods, for example, it can be formulated into dosage forms such as lotion, cream, ointment, lotion, foundation, oil, facial mask, soap (including medicated soap), shower gel, lipstick, nail cosmetics, eye cosmetics, perfume, facial cleanser, oral care products such as toothpaste, mouthwash, etc., deodorant, bath gel, shampoo, hair conditioner, hair tonic, hair gel and hair dye. At the same time, the form of various compositions mixed with the ingredients according to the present invention can be arbitrarily used in the form of solution type, ointment type, paste type, gel type, sol type, foam type, solid type and powder type.
[0048] In another aspect, the present disclosure relates to a graft material (graft), which contains a peptide as an active ingredient, and the peptide has the amino acid sequence of sequence 1. The graft material can cover graft materials in various fields such as skin graft materials, bone graft materials, musculoskeletal regeneration materials, nerve regeneration materials, vascular regeneration materials, etc. The peptide having the amino acid sequence of sequence 1 can be used in combination with various graft material matrices such as extracellular matrix proteins, bone minerals, chitosan, biodegradable polymers, etc.
[0049] Extracellular matrix protein can be any one or more selected from the group consisting of collagen, hyaluronic acid, elastin, chondroitin sulfate and silk fibroin. For these extracellular matrixes, recombinant proteins derived from humans and animals and produced by microorganisms can be used. Among the extracellular matrix proteins, collagen may be the most suitable. Collagen is formed by fibroblasts in the human body and is the main component of the most common connective tissue in the body. It is a fibrous protein distributed throughout the body such as bones, skin, joints, membranes of various organs and hair. At the same time, a large amount of collagen is also present around the axons of central and peripheral nerves. Since the collagen hydrogel present in the body has slightly different functions and effects according to the tissue position, the collagen concentration and orientation degree of the collagen hydrogel at each position are different. For example, the characteristic of bones is that there is a structure in which micron / nanocrystalline minerals are located between oriented collagen fibers. Collagen is an absorbent substance in the body. Due to easy decomposition, when implanted in the body, it can be gradually decomposed so that it is replaced by regenerated bone, so it is suitable as a transplant material matrix. As the collagen, type 1 or type 3 collagen isolated from pig skin is preferably used.
[0050] The bone mineral component may be one or more selected from the group consisting of biogenic bone mineral powder from allogeneic bone or xenogeneic bone, synthetic hydroxyapatite, and calcium phosphate cement (CPC) powder containing tetracalcium phosphate (TTCP), dicalcium phosphate anhydrous (DCPA), and monocalcium phosphate monohydrate (MCPM).
[0051] The biodegradable polymer may be any one or more selected from the group consisting of polyglycolide, polylactide, polyglycolide-lactide and polycaprolactone.
[0052] The graft material matrix can be in the form of a formulation consisting of a batter, powder, putty, gel, hydrogel, matrix, granules, particles, freeze-dried powder, freeze-dried bone, demineralized freeze-dried bone, fresh or fresh frozen bone, a mixture of cortical and cancellous bones, a pellet, a strip, a plug, a membrane, a freeze-dried powder returned to water to form a wet cake, a sphere, a sponge, a block, a morsel, a stick, a wedge, cement, or amorphous particles.
[0053] In one embodiment, the transplant material can be present as a combination of a first agent and a second agent, wherein the first agent has collagen as a main component, and the second agent contains a peptide having an amino acid sequence of sequence 1 and is formulated to be able to impregnate the first agent, and the first agent and the second agent can be mixed before transplantation and used.
[0054] The first dose with collagen as the main component can include a collagen sponge block with a size of 6X5X7mm or 8X7X9mm, and a collagen and bone mineral complex with a size of 6X6X3mm, 6X6X6mm, 7X8X9mm, 9X10X11mm. The first dose and the second dose can be mixed before transplantation. When mixed before transplantation, it has the advantage of keeping collagen and peptide in a sterile state.
[0055] The peptide may contain 10 -4 ~0.5 parts by weight, more preferably 10 -3 ~10 -1 This is because if the peptide content is less than 10 -3 If the peptide content is less than 0.5 parts by weight, the regeneration effect is not significant, and if the peptide content is greater than 0.5 parts by weight, it is difficult to include it in the transplant material.
[0056] Preferred experimental examples are given below to help understand the present invention, but the following experimental examples are only used to illustrate the present invention, and the scope of the present invention is not limited to the following experimental examples.
[0057] Peptide synthesis
[0058] For the peptide of sequence 1, the synthesis was performed from the C-terminus by F-moc solid phase chemical synthesis using a synthesis device. That is, Rink resin (0.075mmol / g, 100-200mesh, 1% DVB cross-linking) with Fmoc-(9-fluorenylmethoxycarbonyl) as a blocking group was used for synthesis. After adding 50mg of RinkAmide MBHA resin to the synthesizer, the resin was swollen with DMF, and then a 20% piperidine / DMF solution was used to remove the Fmoc-group. 5 equivalents, 10 equivalents, and 5 equivalents of 0.5M amino acid solution (solvent: DMF), 1.0M DIPEA (solvent: DMF&NMP), and 0.5M HBTU (solvent: DMF) were added from the C-terminus in sequence and reacted for 1-2 hours under a nitrogen flow. At the end of each deprotection and coupling step, the reaction mixture was washed twice with DMF and methanol. After the last amino acid was coupled, deprotection was performed to remove the Fmoc-group.
[0059] The synthesis was confirmed by the ninhydrin test. After the resin that had been synthesized was dried, 20 ml of Reagent K cleavage cocktail was added per gram of resin and shaken for 3 hours. The cocktail containing the resin and peptide was then separated by filtration. For the solution filtered by the filter, cold ether was added to crystallize the peptide into a solid phase, which was then centrifuged. At this time, the Reagent K cleavage cocktail was completely removed by washing with ether several times and centrifuging. The crude product thus obtained was dissolved in distilled water and separated and purified by liquid chromatography. The purified peptide was freeze-dried. The purity was analyzed by liquid chromatography, and the results of mass spectrometry are shown in FIG. Figure 1 and Figure 2 middle.
[0060] Reference Figure 1 and Figure 2 It was confirmed that the synthesized peptide had a purity of 98.2%, a molecular weight of 1733.99, and consisted of a 15-mer amino acid sequence.
[0061] Evaluation of anti-inflammatory ability
[0062] 1) Determination of the production of pro-inflammatory cytokines (IL-6 and TNF-α)
[0063] The anti-inflammatory ability was verified using human monocytic cell lines (THP-1, ATCC, TIB-202). For monocytic cell lines, PMA (phorbol 12-myristate-13-ethyl ester, Merck, P1585) was inoculated to differentiate from monocytes into macrophages, and then treated with 1μg / ml LPS (lipopolysaccharide, Merck, L3024) as an inflammatory mediator. After 16 hours, 200μM of a peptide with amino acids of sequence 1 and 20ng / ml of IL-4 (R&D system, 204-IL-010 / CF) were inoculated as a positive control group, and the culture fluid of the cells was obtained after 24 hours. The amount of proinflammatory cytokines IL-6 (R&D system, D6050) and TNF-α (R&D system, DTA00D) secreted by cells in the culture medium was confirmed by ELISA (enzyme-linked immunosorbent assay).
[0064] The results, such as Figure 3 As shown, it was confirmed that when treated with a peptide having the amino acid sequence of sequence 1 (LPS+S3), IL-6 and TNF-α values were reduced to a level similar to that when treated with IL-4. When treated with LPS alone, IL-6 and TNF-α values increased. This shows that the peptide having the amino acid sequence of sequence 1 has an anti-inflammatory effect.
[0065] 2) Western blotting of pNFkB and plkBa
[0066] Raw264.7 cells were purchased from ATCC (American Type Culture Collection) and used in the experiment. For Raw264.7 cells, DMEM (Dulbecco's Modified Eagle's) medium supplemented with 10% FBS and 100 unit / ml antibiotics (penicillin-streptomycin) was used and cultured in a CO2 incubator at 37°C supplied with 5% CO2 and 95% air.
[0067] Raw264.7 cells were treated with 200 μM of a peptide having the amino acid sequence of sequence 1 for 30 minutes, and then treated with 1 μg / ml LPS (lipopolysaccharide, Merck, L3024). After 8 hours, the treated cells were collected, and then a protease inhibitor cocktail and a phosphatase inhibitor cocktail were added to a radioimmunoprecipitation buffer (RIPA buffer solution, Thermo Fisher, 89900), and the cells were treated to lyse the cells. The cell lysate was centrifuged and the supernatant was recovered. The concentration of the cell lysate was then determined by the bicinchoninic acid method (BCA assay, Thermo Fisher, 23227). The cell lysate was finally made into 5 mg / ml by adding RIPA buffer solution. Then, it was mixed with a buffer solution composed of 1M Tris-HCl (pH 6.8), 50% glycerol, and 10% SDS in a ratio of 4:1, and then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Then, the polyacrylamide gel was transferred to a nitrocellulose membrane and blocked with a blocking solution (5% skim milk in Tris-buffered saline with 0.1% 20) After the membrane was blocked, the primary antibodies (phosphorylated NF-κB (Signaling Technology, 3033), NF-κB (Signaling Technology, 8242), phosphorylated IκBα (Cell Signaling Technology, 9246), IκBα (Cell Signaling Technology, 4812), β-actin (Santa Cruz Biotechnology, sc-47778)) were reacted with the blocking solution at a ratio of 1:1000 under refrigeration overnight. Then, the secondary antibody corresponding to each primary antibody was reacted with the blocking solution at a ratio of 1:2000 at room temperature for 1 hour, and then reacted with ECL (enhanced chemiluminescence, Thermo Fisher, 34094) solution, and the membrane was developed using the ChemiDoc imaging system (Bio-Rad). Phosphorylated NF-κB and phosphorylated plkBa are indicators that can confirm the degree of inflammatory response at the cellular level. The higher the degree of inflammatory response, the more phosphorylated NF-κB and phosphorylated plkBa are expressed.
[0068] The results, such as Figure 4As shown, when treated with LPS alone, the expression of pNFκB and plkBa increased, but when treated with a peptide having the amino acid sequence of sequence 1 and then treated with LPS, the expression of pNFκB and plkBa was inhibited. This shows that the peptide having the amino acid sequence of sequence 1 has an anti-inflammatory effect.
[0069] However, when treated only with a peptide having the amino acid sequence of sequence 1, the expression of pNFκB and plkBa of cells was not affected, which indirectly proved that the peptide was safe.
[0070] Evaluation of antimicrobial ability
[0071] 1) Inhibit the growth of periodontitis pathogens
[0072] In order to evaluate the antibacterial ability, representative periodontitis pathogens such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used. Each bacterium was inoculated into BHI (brain heart infusion) liquid culture medium and then cultured in an anaerobic incubator at 37°C and 120rpm for 48 hours. After cultivation, it was treated with a peptide having the amino acid sequence of sequence 1 to 100μM, 250μM, and 500μM. Minocycline (Merck, M9511) 500ng / ml was inoculated as a positive control group, and the absorbance was measured at a wavelength of 600nm using a spectrophotometer after 24 hours to confirm the growth degree of the bacteria.
[0073] The results, such as Figure 5 As shown, when treated with a peptide having the amino acid sequence of sequence 1, for Aa (Aggregatibacter actinomycetemcomitans), the bacterial survival rate was less than 50% when the concentration was above 250 μM, and for Pg (Porphyromonas gingivalis), the bacterial survival rate was less than 50% when the concentration was above 100 μM.
[0074] On the other hand, compared with the effect of minocycline, when Aa was treated at a concentration of 500 μM, the survival rate was higher than that when treated with minocycline 500 ng / ml, but similar effects were shown. In the case of minocycline, only antibacterial ability was present, while in the case of the peptide having the amino acid sequence of sequence 1, both antibacterial ability and anti-inflammatory ability were present, so even if there was a slight difference in antibacterial ability, that part could be compensated. For Pg, an effect superior to minocycline was shown in all concentration ranges.
[0075] 2) Evaluation of antibacterial ability in biofilm
[0076] Periodontitis-causing bacteria in the oral cavity exist in the form of biofilm. In order to simulate this situation, artificial biofilms were made on the surface of titanium disks using Aa (Aggregatibacter actinomycetemcomitais) and Pg (Porphyromonas gingivalis). Saliva and bacteria were mixed on the titanium disk and placed in BHI liquid culture medium, which was then cultured in an anaerobic incubator at 37°C. After 72 hours, 50μg / ml (=29μM), 100μg / ml (=58μM), 250μg / ml (=144μM), 500μg / ml (=288μM) of peptides were inoculated, and 1μg / ml of minocycline was inoculated as a positive control group. 24 hours after inoculation, a titanium disk with a biofilm formed on the surface was obtained, and Filmtracer was used to analyze the biofilm. TM LIVE / DEAD TM Biofilm viability kit (Thermo Fisher, L10316) was used to stain the biofilm. Live bacteria were stained green and dead bacteria were stained red. The titanium disk was observed using a confocal scanning fluorescence microscope.
[0077] The results, such as Figure 6 As shown, in the case of minocycline used as a positive control group, almost no bacteria (red) were observed to be killed, because it was not possible to penetrate the biofilm to kill bacteria. On the other hand, when the peptide having the amino acid sequence of sequence 1 was treated, bacteria (red) were observed to be killed starting from a concentration of 50 μg / ml (= 29 μM). Therefore, although the existing antibiotics cannot kill bacteria existing in the form of biofilms, in the case of the peptide having the amino acid sequence of sequence 1, it can be confirmed that it penetrates into the biofilm and has antibacterial ability.
[0078] Evaluation of cell / tissue penetration
[0079] 1) Evaluate cell permeability at the cellular level
[0080] The N-terminus of the peptide with amino acids of sequence 1 prepared in Example 1 was fluorescently labeled with rhodamine B (Tokyo Chemical Industry Co., Ltd., A5102). Raw264.7 cells were distributed to a 4-well chamber, 3X104 cells were distributed to each well, and cultured in DMEM medium for 24 hours to stabilize the cells. After 24 hours, the fluorescently labeled peptide was added to the culture medium at a concentration of 50, 100, and 200 μM. After 1 hour of peptide treatment, the degree of intracellular peptide penetration was observed using a confocal scanning fluorescence microscope. For the nucleus of the cell, 4', 6-diamidino-2-phenylindole (DAPI, Thermo Fisher, D1306) was used for staining. DIC represents the situation observed with an ordinary microscope, Nuceli represents the nucleus of the cell, Peptide represents the degree of penetration of the peptide bound to rhodamine B, and MERGE represents an image in which the images of DIC, Nuclei, and the infiltrated peptide are overlapped.
[0081] The results, such as Figure 7 As shown, the fluorescence of rhodamine B (red) was observed in cells treated with the peptide having the amino acid sequence 1, but no red color was observed in the untreated experimental group. In addition, it can be seen that the fluorescence intensity increases with the increase in peptide concentration.
[0082] 2) Evaluate tissue penetration in animal tissues
[0083] Using Alexa Fluor TM The amine groups of the peptides with the amino acids of sequence 1 were fluorescently labeled with 680 NHS ester (Thermo Fisher Scientific, A20008). The fluorescent labeling method followed the method provided by the manufacturer. The fluorescently labeled peptide was dissolved in water for injection at a concentration of 250 mg / ml, and 10 μL was injected into the gingival sulcus of the premolars of adult dogs (beagledog) and the gingival sulcus of the anterior teeth of rabbits (rabbit). After 2 hours, in order to confirm the penetration rate of the peptide in the tissue, the animals were sacrificed, the gingival tissue was collected and the gingival tissue was used for 30 min. The tissue was embedded in OCT Compound (Sakura Finetek, 4583). The embedded tissue was sliced into 10 μm thick sections, and the fluorescently labeled peptide was confirmed using a confocal scanning fluorescence microscope. The nuclei of the tissue cells were stained with DAPI.
[0084] from Figure 8 The gingival tissue of rabbits and Fig. 9 The results of adult dog gingival tissue confirmed that the fluorescently labeled peptide penetrated the gingival tissue cells and reached a diameter of about 500 (440-459) μm.
[0085] Therefore, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 penetrates not only at the cellular level but also penetrates into tissues.
[0086] Evaluation of the antimicrobial capacity of transplant materials
[0087] A collagen sponge block of 6X5X7mm in size was impregnated with a peptide having the amino acid sequence 1 at 500μg / 0.5ml, and then placed at 4°C for 8 hours and freeze-dried. As a positive control group, minocycline (Merck, M9511) 250ng / 0.5ml was impregnated in a collagen sponge block of 6X5X7mm in size, and then placed at 4°C for 8 hours and freeze-dried. In order to evaluate the antibacterial ability of the transplant material containing the peptide having the amino acid sequence 1, representative periodontitis pathogens such as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used. After each bacterium was inoculated into BHI (brain heart infusion) liquid culture medium, it was cultured in an anaerobic incubator at 37°C and 120rpm for 48 hours. After culture, the collagen sponge block containing the peptide having the amino acid sequence of sequence 1 of Example 2 was added to the culture medium. After 24 hours, the absorbance was measured at a wavelength of 600 nm to confirm the degree of bacterial growth.
[0088] The results, such as Fig.10 As shown, when the collagen sponge block containing the peptide having the amino acid sequence of sequence 1 was treated, the survival rate of bacteria for Aa (Aggregatibacter actinomycetemcomitans) and Pg (Porphyromonas gingivalis) was less than 40%. Therefore, it was proved that the peptide having the amino acid sequence of sequence 1 also had an antibacterial effect when applied to the collagen sponge block.
[0089] Evaluation of periodontal tissue regeneration ability of transplant materials
[0090] Collagen gel was dissolved in 0.1 M PBS at a concentration of 4%. 125 mg of the peptide having the amino acid sequence 1 was dissolved in 1 g of collagen gel. As a positive control group, 20 mg of minocycline was dissolved in the same 1 g of collagen gel.
[0091] In order to evaluate the periodontal tissue regeneration ability of transplant materials containing peptides with amino acids of sequence 1, collagen sponges containing peptides were implanted after periodontitis was induced in beagle dogs. To induce periodontitis, dental wire was used to wrap several layers around the cervical areas of the 2nd, 3rd, and 4th teeth of the mandibular premolars to induce periodontitis. After wrapping the wire for three months, the wire was removed for scaling and root planning. 15 μl of collagen gel containing peptides with amino acids of sequence 1 and collagen gel containing minocycline were applied to the gingival sulcus twice a week for 5 weeks. The periodontal status was observed for 12 weeks, and alveolar bone regeneration was observed by X-ray photography. The results, such as Fig.11 and Fig.12 As shown, the group (NT) to which no substance was applied did not generate alveolar bone after 12 weeks. The group implanted with collagen gel containing minocycline showed a similar degree of alveolar bone regeneration as the NT group. However, when collagen gel using peptides with amino acids of sequence 1 was implanted, the regeneration of alveolar bone (white part in the box) increased by more than 10 times compared to the group implanted with collagen gel containing minocycline. Therefore, it was proved that collagen gel using peptides with amino acids of sequence 1 has an excellent effect on periodontal tissue regeneration.
[0092] Although the experimental examples are described above, the scope of the rights is not limited thereto. The implementation method can be modified into various methods within the scope of the specification and the drawings, which of course also fall within the scope of the rights.
[0093] Industrial Applicability
[0094] It can be used as a pharmaceutical composition for treating inflammatory diseases or bacterial diseases or conditions. It can be used as a pharmaceutical composition for treating periodontal diseases such as periimplantitis, periodontitis, etc.
[0095] Sequence Listing Free Text
[0096] Sequence 1: GKCSTRGRKS SRRKK
Claims
1. A peptide with anti-inflammatory ability, which consists of the amino acid sequence of sequence 1.
2. An anti-inflammatory pharmaceutical composition comprising the peptide according to claim 1 as an active ingredient.
3. The anti-inflammatory pharmaceutical composition according to claim 2, wherein The anti-inflammatory pharmaceutical composition is used for treating dental infection diseases.
4. A peptide having antibacterial activity against bacteria and biofilms, which consists of the amino acid sequence of sequence 1.
5. An antibacterial pharmaceutical composition comprising the peptide according to claim 4 as an active ingredient.
6. The antibacterial pharmaceutical composition according to claim 5, wherein The antibacterial pharmaceutical composition is used for treating dental infection diseases.
7. A peptide with anti-inflammatory and antibacterial abilities, which consists of the amino acid sequence of sequence 1.
8. An anti-inflammatory and antibacterial pharmaceutical composition comprising the peptide of claim 7 as an active ingredient.
9. The anti-inflammatory pharmaceutical composition according to claim 5, wherein The anti-inflammatory and antibacterial pharmaceutical composition is used for treating dental infection diseases.
10. A peptide having cell-penetrating ability and tissue-penetrating ability, which consists of the amino acid sequence of sequence 1.
11. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
12. The pharmaceutical composition according to claim 11, wherein The pharmaceutical composition is used for treating dental infection diseases.
13. The pharmaceutical composition according to claim 12, wherein The dental infection disease is gingivitis, periodontitis or peri-implantitis.
14. A transplant material comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
15. The transplant material according to claim 14, wherein The transplant material comprises extracellular matrix protein, bone mineral, chitosan or biodegradable polymer.
16. The transplant material according to claim 14, wherein The transplant material comprises 10 -4 0.5 parts by weight of a peptide consisting of the amino acid sequence of sequence 1.
17. The transplant material according to claim 14, wherein The transplant material has antibacterial, anti-inflammatory or periodontal tissue regeneration capabilities.
